A genetic basis for coronary artery disease

Trends in Cardiovascular Medicine

Volumn 25, Issue 3, 2015, Pages 171-178

  Roberts, Robert ^a,b  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b Ruddy Canadian Cardiovascular Genetics Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; DNA; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CORONARY ARTERY DISEASE; GENE MUTATION; GENE TECHNOLOGY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC REGULATION; GENETIC RISK; GENETIC VARIABILITY; GENETICS; HEART INFARCTION; HEREDITY; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; PCSK9 MOUSE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; BLOOD; RISK FACTOR;

CORONARY ARTERY DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PROPROTEIN CONVERTASES; RISK FACTORS; SERINE ENDOPEPTIDASES; TRIGLYCERIDES;

EID: 84925160718     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2014.10.008     Document Type: Review

References (65)

1. Ku C.S., Naidoo N., Pawitan Y. Revisiting Mendelian disorders through exome sequencing. Hum Genet 2011, 129:351-370.
2. Jarcho J.A., McKenna W., Pare J.A., Solomon S.D., Holcombe R.F., Dickie S., et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. N Engl J Med 1989, 321:1372-1378.
3. Hejtmancik J.F., Brink P.A., Towbin J., Hill R., Brink L., Tapscott T., et al. Localization of gene for familial hypertrophic cardiomyopathy to chromosome 14q1 in a diverse US population. Circulation 1991, 83:1592-1597.
4. Olson T.M., Michels V.V., Thibodeau S.N., Tai Y.S., Keating M.T. Actin mutations in dilated cardiomypathy, a heritable form of heart failure. Science 1998, 280:750-752.
5. Gollob M.H., Green M.S., Tang A.S., Gollob T., Karibe A., Ali Hassan A.S., et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 2001, 344:1823-1831.
6. Brugada R., Tapscott T., Czernuszewicz G.Z., Marian A.J., Iglesias A., Mont L., et al. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med 1997, 336:905-911.
7. Wang Q., Shen J., Splawski I., Atkinson D., Li Z., Robinson J.L., et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995, 80:805-811.
8. Chen Q., Kirsch G.E., Zhang D., Brugada R., Brugada J., Brugada P., et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998, 392:293-296.
9. Chronic Disease Prevention Alliance of Canada. Investing in our future: preventing chronic diseases in Canada. 2003.
10. American Heart Association Heart Disease and Stroke Statistics-2005 Update 2005, American Heart Assocation, Dallas, Texas.
11. Murray C.J., Lopez A.D. Measuring the global burden of disease. N Engl J Med 2013, 369:448-457.
12. Wald N.J., Law M.R. A strategy to reduce cardiovascular disease by more than 80%. Br Med J 2003, 326:1419-1423.
13. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. INTERHEART study investigators. Lancet 2004, 364:937-952.
14. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301-1308.
15. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. J Am Med Assoc 1998, 279:1615-1622.
16. Roberts R. Personalized Medicine: an Idea whose time is approaching. Methodist Debakey Cardiovasc J 2007, 3:3-7.
17. Roberts R., Wells G.A., Stewart A.F., Dandona S., Chen L. The genome-wide association study-a new era for common polygenic disorders. J Cardiovasc Transl Res 2010, 3:173-182.
18. Morgan T., Carney S., Roberts R. Changes in plasma renin activity and blood pressure after acute and chronic administration of beta-adrenergic receptor-blocking drugs. Clin Sci Mol Med Suppl 1975, 2:81s-83ss.
19. Anand S., Xie C., Pare G., Montpetit A., Rangarajan S., McQueen M.J., et al. Genetic variants associated with myocardial infarction risk factors in over 8000 individuals from five ethnic groups-INTERHEART Study. Circ Cardiovasc Genet 2009, 2:16-25.
20. Roberts R. New gains in understanding coronary artery disease. Interview with Dr. Robert Roberts. Affymetrix Microarray Bull 2007, 3:1-4.
21. LaFramboise T. Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances. Nucleic Acids Res 2009, 37:4181-4193.
22. Gibbs R.A. The International HapMap Project. Nature 2003, 426:789-796.
23. Risch N., Merikangas K. The future of genetic studies of complex human diseases. Science 1996, 273:1516-1517.
24. Petretto E., Liu E.T., Aitman T. A gene harvest revealing the archeology and complexity of human disease. Nat Genet 2007, 39:1299-1301.
25. Roberts R., Stewart A.F., Wells G.A., Williams K.A., Kavaslar N., McPherson R. Identifying genes for coronary artery disease: an idea whose time has come. Can J Cardiol 2007, 23(Suppl. A):7A-15A.
26. McPherson R., Pertsemlidis A., Kavaslar N., Stewart A., Roberts R., Cox D.R., et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007, 316:1488-1491.
27. Helgadottir A., Thorleifsson G., Manolescu A., Gretarsdottir S., Blondal T., Jonasdottir A., et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007, 316:1491-1493.
28. Dandona S., Stewart A.F., Roberts R. Genomics in coronary artery disease: past, present and future. Can J Cardiol 2010, 26(Suppl. A):56A-59AA.
29. Helgadottir A., Thorleifsson G., Magnusson K.P., Grétarsdottir S., Steinthorsdottir V., Manolescu A., et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet 2008, 40:217-224.
30. Beckie T.M., Beckstead J.W., Groer M.W. The association between variants on chromosome 9p21 and inflammatory biomarkers in ethnically diverse women with coronary heart disease: a pilot study. Biol Res Nurs 2011, 13:306-319.
31. Roberts R. Genetics of coronary artery disease. Circ Res 2014, 114:1890-1903.
32. Dandona S., Stewart A.F., Chen L., Williams K., So D., O[U+05F3]Brien E., et al. Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J Am Coll Cardiol 2010, 56:479-486.
33. Horne B.D., Carlquist J.F., Muhlestein J.B., Bair T.L., Anderson J.L. Association of variation in the chromosome 9p21 locus with myocardial infarction versus chronic coronary artery disease. Circ Cardiovasc Genet 2008, 1:85-92.
34. Reilly M.P., Li M., He J., Ferguson J.F., Stylianou I.M., Mehta N.N., et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 2011, 377:383-392.
35. Ardissino D., Berzuini C., Merlini P.A., Mannucci P., Surti A., Burtt B., et al. Influence of 9p21.3 genetic variants on clinical and angiographic outcomes in early-onset myocardial infarction. J Am Coll Cardiol 2011, 58:426-434.
36. Hinohara K., Nakajima T., Takahashi M., Hohda S., Sasaoka T., Nakahara K., et al. Replication of the association between a chromosome 9p21 polymorphism and coronary artery disease in Japanese and Korean populations. J Hum Genet 2008, 53:357-359.
37. Preuss M., Konig I.R., Thompson J.R., Erdmann J., Absher D., Assimes T.L., et al. Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) study: a Genome-wide association meta-analysis involving more than 22,000 cases and 60,000 controls. Circ Cardiovasc Genet 2010, 3:475-483.
38. Schunkert H., Konig I.R., Kathiresan S., Reilly M.P., Assimes T.L., Holm H., et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 2011, 43:333-338.
39. The Coronary Artery Disease (C4D) Genetics Consortium A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet 2011, 43:339-344.
40. IBC 50K CAD Consortium Large-scale gene-centric analysis identifies novel variants for coronary artery disease. PLoS Genet 2011, 7:e1002260.
41. Deloukas P., Kanoni S., Willenborg C., Farrall M., Assimes T.L., Thompson J.R., et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2013, 45:25-33.
42. Wise A.L., Gyi L., Manolio T.A. eXclusion: toward integrating the X chromosome in genome-wide association analyses. Am J Hum Genet 2013, 92:643-647.
43. Stranger B.E., Forest M.S., Dunning M., Ingle C.E., Beazley C., Thorne N., et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 2007, 315:848-853.
44. Cavalli-Sforza L.L., Feldman M.W. The application of molecular genetic approaches to the study of human evolution. Nat Genet 2003, 33(Suppl.):266-275.
45. McDougall I., Brown F.H., Fleagle J.G. Stratigraphic placement and age of modern humans from Kibish, Ethiopia. Nature 2005, 433:733-736.
46. Finlayson C. Biogeography and evolution of the genus Homo. Trends Ecol Evol 2005;20:457-63.
47. Levin L., Zhidkov I., Gurman Y., Hawlena H., Mishmar D. Functional recurrent mutations in the human mitochondrial phylogeny: dual roles in evolution and disease. Genome Biol Evol 2013, 5:876-890.
48. Carlson Chris Considerations for SNP selection. Genetic variation: a laboratory manual 2007, 263-281. Cold Spring Harbor Laboratory Press. P. Michael, S.G.J.C.S. Winer (Eds.).
49. Bhangale T.R., Rieder M.J., Livingston R.J., Nickerson D.A. Comprehensive identification and characterization of diallelic insertion-deletion polymorphisms in 330 human candidate genes. Hum Mol Genet 2005, 14:59-69.
50. Sun J.X., Helgason A., Masson G., Ebenesersdóttir S.S., Li H., Mallick S., et al. A direct characterization of human mutation based on microsatellites. Nat Genet 2012, 44:1161-1165.
51. Brown M.S., Goldstein J.L. Familial hypercholesterolemia: a genetic defect in the low-density lipoprotein receptor. N Engl J Med 1976, 294:1386-1390.
52. Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S.B., Stifani S., et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003, 100:928-933.
53. Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264-1272.
54. Graham M.J., Lemonidis K.M., Whipple C.P., Subramaniam A., Monia B.P., Crooke S.T., et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007, 48:763-767.
55. Wierzbicki A.S., Hardman T.C., Viljoen A. Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia. Expert Opin Investig Drugs 2012, 21:667-676.
56. Sjouke B., Kusters D.M., Kastelein J.J., Hovingh G.K. Familial hypercholesterolemia: present and future management. Curr Cardiol Rep 2011, 13:527-536.
57. Ni Y.G., Di Marco S., Condra J.H., Peterson L.B., Wang W., Wang F., et al. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res 2011, 52:78-86.
58. Stein E.A., Mellis S., Yancopoulos G.D., Stahl N., Logan D., Smith W.B., et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012, 366:1108-1118.
59. Hovingh G.K., Davidson M.H., Kastelein J.J., O[U+05F3]Connor A.M. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J 2013, 34:962-971.
60. Roberts R. Genetics of premature myocardial infarction. Curr Atheroscler Rep 2008, 10:186-193.
61. Rader D.J., Maugeais C. Genes influencing HDL metabolism: new perspectives and implications for atherosclerosis prevention. Mol Med Today 2000, 6:170-175.
62. Cohen J.C., Kiss R.S., Pertsemlidis A., Marcel Y.L., McPherson R., Hobbs H.H. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004, 305:869-872.
63. Teslovich T.M., Musunuru K., Smith A.V., Edmondson A.C., Stylianou I.M., Koseki M., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466:707-713.
64. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013; 45):1274-83.
65. Huan T., Zhang B., Wang Z., Joehanes R., Johnson A.D., Ying S., et al. A systems biology framework identifies molecular underpinnings of coronary heart disease. Arterioscler Thromb Vasc Biol 2013, 33:111-119.